The hOGG1 Ser326Cys polymorphism contributes to cancer susceptibility: evidence from 83 case-control studies.

The Ser326Cys polymorphism in the human 8-oxogunaine DNA glycosylase (hOGG1) gene had been implicated in cancer susceptibility. Studies investigating the associations between the Ser326Cys polymorphism and cancer susceptibility showed conflicting results. To derive a more precise estimation of the relationship, a meta-analysis was performed. This meta-analysis was performed from 83 case-control studies, including 27,918 cases and 33,399 controls. The fixed and random effect models were used to estimate the odds ratios (ORs) and their 95% confidence interval (CI) for various contrasts of this polymorphism. The combined results based on all studies showed that the hOGG1 Ser326Cys polymorphism was associated with an increased cancer susceptibility in different genetic models. In the stratified analyses, the association was significantly in head and neck cancer (homozygote comparison: OR = 2.19, 95% CI: 1.20-4.01, P(heterogeneity) = 0.002; heterozygote comparison: OR = 1.48, 95% CI: 1.11-1.99, P(heterogeneity) = 0.004; dominant model comparison: OR = 1.58, 95% CI: 1.14-2.19, P(heterogeneity) < 0.001; recessive model comparison: OR = 1.73, 95% CI: 1.02-2.94, P(heterogeneity) = 0.002; and additive model comparison: OR = 1.43, 95% CI: 1.09-1.88, P(heterogeneity) < 0.001) which remained for studies of the Asian populations and hospital-based of control sources. But it was not observed in other cancer types of the European population and population based of control sources. This meta-analysis suggested that the hOGG1 Ser326Cys polymorphism might contribute to an increased risk on cancer susceptibility. More studies based on larger sample size should be performed to confirm the findings.